Search Results
Your search for ,itS matches 8761 pages
Showing 2001 - 2050NCCN Guidelines for Prostate Cancer: Panel Clarifies Role of Active Surveillance for Low-Risk Prostate Cancer
In October 2021, the National Comprehensive Cancer Network (NCCN) prostate caycer panel modified its guidelines (NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines®]) for low-risk prostate cancer to remove the word “preferred option” for active surveillance, giving equal weight to...
2021 FDA Approvals of Drugs for Cancer Treatment
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to many novel drugs and new indications for older therapeutic agents used in oncology and hematology. NOVEMBER Pafolacianine for Ovarian Cancer Lesions: On November 29, pafolacianine (Cytalux), an imaging drug,...
Addition of First-Line Veliparib to Chemotherapy in Advanced Squamous Cell NSCLC: No Survival Benefit in Current Smokers, but Potential Benefit Among Biomarker-Selected Patients
In a phase III trial reported in the Journal of Clinical Oncology, Suresh S. Ramalingam, MD, of Winship Cancer Institute, Emory University School of Medicine, and colleagues found that the addition of the PARP inhibitor veliparib to platinum-based chemotherapy did not improve overall survival in...
Diversity in Clinical Trials Career Development Program
The Bristol Myers Squibb Foundation, the National Medical Fellowships, and the American Association for Cancer Research (AACR) recently announced the first group of 52 physicians selected for its Diversity in Clinical Trials Career Development Program. The 52 physicians selected by an independent...
Solving the Conundrum of Young-Onset Colorectal Cancer
Although research so far has failed to uncover the root causes of the development of young-onset colorectal cancer, what is certain is that although colorectal cancer rates are declining in older adults, they are on a steady rise in people younger than age 50, especially those between the ages of...
Association of CD123 Expression With High-Risk Disease Characteristics and Outcomes in Pediatric AML
In an analysis from the Children’s Oncology Group AAML1031 trial reported in the Journal of Clinical Oncology, Lamble et al found that increased CD123 expression was associated with high-risk genetic alterations and poorer treatment outcomes in pediatric patients with newly diagnosed acute myeloid...
Positive Practice Changes After the COVID-19 Pandemic: From the Advanced Practice Provider Perspective
The COVID-19 pandemic may have changed some aspects of health care forever. At the 2021 JADPRO Live Virtual event, a panel discussion focused on how several cancer centers faced challenges, and what changes the participants view as positive.1 JADPRO Live is an annual educational conference for...
WHO Launches a New Classification System for Pediatric Tumors, Incorporating Morphology, Immunohistochemistry Analysis, and Molecular Characteristics
A review article by Pfister et al published in Cancer Discovery summarizes the inaugural classification of pediatric tumors soon to be published by the International Agency for Research on Cancer as part of the new World Health Organization (WHO) Classification of Tumors series, including an online ...
Study Examines a Potential Approach to Mitigate CAR T-Cell Therapy Toxicity
Research demonstrating a novel approach that may reduce cytokine-release syndrome associated with chimeric antigen receptor (CAR) T-cell therapy was presented by Marcela Maus, MD, PhD, and colleagues at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract 1723)...
American Cancer Society Releases Updated Report on Status of Cancer Disparities in the United States
The American Cancer Society recently released its report on the status of cancer disparities in the United States for 2021. Researchers analyzed comprehensive and up-to-date data on racial/ethnic and socioeconomic disparities in cancer occurrence; this includes incidence, stage at diagnosis,...
POLARIX: Pola-R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL
The POLARIX study found patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression 2 years after receiving a new drug combination known as pola-R-CHP (polatuzumab vedotin-piiq with rituximab, cyclophosphamide, doxorubicin, and...
ZUMA-7 Primary Analysis: Second-Line Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care in the second-line treatment of relapsed or refractory large B-cell lymphoma, according to...
Isatuximab/RVd Meets Primary Endpoint of MRD Negativity for Newly Diagnosed, Transplant-Eligible Patients With Multiple Myeloma
For the first-line treatment of newly diagnosed, transplant-eligible patients with multiple myeloma, the achievement of measurable residual disease (MRD) negativity was significantly greater when the anti-CD38 monoclonal antibody isatuximab was added to the standard three-drug induction regimen of...
TRANSFORM Trial: Lisocabtagene Maraleucel vs Standard of Care for Relapsed or Refractory Large B-Cell Lymphoma
An interim analysis of the TRANSFORM trial comparing the chimeric antigen receptor (CAR) T-cell immunotherapy lisocabtagene maraleucel to standard of care found that the CAR T-cell therapy significantly improved event-free survival for patients with large B-cell lymphoma that persisted or returned...
The National Cancer Act of 1971
On December 23, 1971, President Richard M. Nixon signed the National Cancer Act into law. At that time, cancer was the nation’s second leading cause of death; only about one of two people diagnosed with cancer survived at least 5 years—compared with two of three people diagnosed with the disease...
I’m Living—and Thriving—With Stage IV Non–Small Cell Lung Cancer
A diagnosis, in 2020, of stage IV adenocarcinoma non–small cell lung cancer (NSCLC) was found accidentally. I was 55 at the time and in the best physical shape of my life. I had spent the previous year and a half on a diet and exercise regimen that had rendered me 35 pounds lighter and feeling...
Expect Questions on Use of Low-Dose Aspirin to Help Prevent Colorectal Cancer
Following a review of new data and additional analyses of previous data concerning colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) “concluded the evidence is inadequate that low-dose aspirin use reduces colorectal cancer incidence or mortality.”1 Consequently, a draft...
Update on the Role of Low-Dose Aspirin in Colorectal Cancer Prevention
Updating its 2016 recommendation on the use of aspirin to prevent cardiovascular disease and colorectal cancer, the U.S. Preventive Services Task Force (USPSTF) issued a draft recommendation statement. It noted the potential harms of daily aspirin, with the most serious being bleeding in the...
The High Price of Pain
According to the Centers for Disease Control and Prevention (CDC), from 1999 to 2019, nearly 247,000 people died from overdoses involving prescription opioids in the United States. According to the CDC, the problem can be broken into three waves. The first began with an increase in prescribing...
Reclaiming a Complicated Genius Who Pursued Cancer With Single-Minded Fury
The Nobel Laureate Otto Warburg was regarded as one of the most significant biochemists of the 20th century, whose exhaustive research led to an understanding of cancer that remains significant to this day. Warburg was also one of the most despised figures in his homeland of Nazi Germany. As a...
Early Operation With General Anesthesia
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
The History of Medical Oncology in Europe, 1955–1985
In part 1 of this two-part review, we looked at early pioneers in the field of medical oncology in Europe, as well as the development of international cooperative trials and the formation of European oncology societies (see related articles below). In part 2, we explore how the field of medical...
MSK Inaugurates New Center for Myelodysplastic Syndromes and Announces New Appointments
Memorial Sloan Kettering Cancer Center (MSK) recently acknowledged the commitment of the Edward P. Evans Foundation to inaugurate The Edward P. Evans Center for Myelodysplastic Syndromes (MDS) at MSK. With the grant of $5 million matched by institutional funds, MSK will establish the Edward P....
ACCC Presents 2021 Annual Awards for Significant Contributions to Oncology Care
The Association of Community Cancer Centers (ACCC) presented its 2021 Annual Awards at the its 38th National Oncology Conference, held virtually on November 9–10. The awards honor individuals who have made significant contributions to patient care, the practice of clinical care and research, and...
Margaret Foti, PhD, MD (hc), Honored With 2021 Tara Withington Public Service Award
The American Association for Cancer Research (AACR) recently congratulated its Chief Executive Officer, Margaret Foti, PhD, MD (hc), on her recognition by the Society for Immunotherapy of Cancer (SITC) with its 2021 Tara Withington Public Service Award. According to the SITC, this award “honors an ...
Three Investigators Named Winners of MSK Cancer Center’s 2021 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce three recipients of this year’s Paul Marks Prize for Cancer Research. The prize recognizes a new generation of leaders in cancer research who are making significant contributions to the understanding of cancer or are improving the...
Mitchell D. Schnall, MD, PhD, Re-elected Group Co-Chair of the ECOG-ACRIN Cancer Research Group
The Principal investigator Committee of the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) re-elected Mitchell D. Schnall, MD, PhD, as the Group Co-Chair, a position he has held since the founding of the Group in 2012. Dr. Schnall will serve in this role from 2021 to 2031. Dr. Schnall co-leads the...
The History of Medical Oncology in Europe, 1955–1985
Our goal with this review of the pivotal years of oncology in Europe is to acknowledge the tremendous contributions of the early leaders in the field and to help young investigators learn from the past to better cope with the inevitable challenges of today and tomorrow. “On ne connaît pas...
COVID-19 Vaccine Requirements for Medicare, Medicaid Facilities, and Employers of 100 or More Staff Released
On November 4, 2021, the Centers for Medicare & Medicaid Services (CMS) issued an interim final rule requiring COVID-19 vaccination of eligible staff at health-care facilities that participate in the Medicare and Medicaid programs, and the Occupational Safety and Health Administration (OSHA)...
Jordan’s Queen Rania Presents King Hussein Awards for Cancer Research
Her Majesty Queen Rania Al Abdullah of Jordan honored recipients of the 2021 King Hussein Award for Cancer Research during ceremony held on November 14 by the King Hussein Cancer Foundation (KHCF). The event was conducted under the patronage of Their Majesties King Abdullah II and Queen Rania Al...
Use of Adjuvant Chemotherapy in Older Patients With Pancreatic Cancer and Its Effect on Overall Survival
In a study reported in JAMA Oncology, Mehtsun et al found patterns of increasing use of adjuvant chemotherapy over time among patients aged ≥ 80 years undergoing pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. In addition, they found that use of adjuvant chemotherapy was associated...
Cleveland Clinic Researcher Receives NIH Director’s Pioneer Award
Michaela Gack, PhD, Scientific Director of Cleveland Clinic’s Florida Research and Innovation Center, has received a National Institutes of Health (NIH) Director’s Pioneer Award to support her research toward the development of broad-spectrum antiviral drugs. The grant is part of NIH’s High-Risk,...
Applying Research Data to Clinical Practice in Managing Head and Neck Cancer
The 2021 Winship Cancer Institute of Emory University Symposium: Updates in the Management of Head and Neck Cancer explored current paradigms for the multidisciplinary treatment of head and neck cancer.1 Moderated by Nabil F. Saba, MD, FACP, the Lynne and Howard Halpern Chair in Head and Neck...
Society for Integrative Oncology Focuses on the Science of Living Well With Cancer
Guest Editor’s Note: With the easing of some COVID-19 restrictions, the Society for Integrative Oncology (SIO) held its 2021 international conference in a hybrid format. It focused on the science of living well with cancer, challenges in designing integrative oncology research, and the role of...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances intreating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
How Medical Oncology Came to Be
For many, the way things are when you learn about them is assumed to be the way things have always been. For example, antibiotics are wonderful—but if you were practicing medicine when penicillin was discovered, it would have seemed like a miracle. For most of us, there have always been chemical...
Establishing a Health Equity Report Card to Eradicate Disparities in Cancer Care
Although enormous progress over the past 50 years in every aspect of cancer care, including prevention, screening, chemotherapy, targeted therapy, surgery, radiation therapy, and supportive care, has resulted in increases in lives saved—from 3 million in 1971 to 16.9 million in 2019—the burden of...
Single-Cell Spatial Analysis May Help to Predict Response to Neoadjuvant Atezolizumab in Patients With Triple-Negative Breast Cancer
A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab to chemotherapy as...
Expert Point of View: Adam M. Brufsky, MD, PhD
Adam M. Brufsky, MD, PhD, Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Comprehensive Breast Cancer Center, commented on the KEYNOTE-355 final analysis1 for The ASCO Post. “We now have a drug with full approval of the U.S. Food and Drug...
Association of Donor Clonal Hematopoiesis With Outcomes in Hematopoietic Stem Cell Transplant Recipients
In a study reported in the Journal of Clinical Oncology, Gibson et al identified significant associations of donor clonal hematopoiesis with outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation (HCT). As stated by the investigators, “Clonal hematopoiesis can be...
Sotigalimab Plus Nivolumab in Anti–PD-1/PD-L1–Refractory Melanoma
Immune checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, but a significant number of patients still fail to respond to anti–PD-1 therapy. The novel combination of sotigalimab, an anti-CD40 monoclonal antibody, and the PD-1 inhibitor nivolumab could help address this...
To Elect or Forgo Radiation Therapy: An Informed Decision for Patients With Breast Cancer
Advances in treating breast cancer “increasingly create opportunities to consider where radiation therapy might safely be omitted,” Reshma Jagsi, MD, DPhil, told participants at the 2021 Lynn Sage Breast Cancer Symposium.1 “But, I would encourage us,” she continued, “not to assume that women who...
Keith T. Flaherty, MD, on Results From the DREAMseq Trial
Invited discussant of the phase III DREAMseq trial, Keith T. Flaherty, MD, said the findings still leave room for nuanced decision-making.1 Dr. Flaherty is Professor of Medicine at Harvard and Director of the Henri and Belinda Termeer Center for Targeted Therapy at the Massachusetts General...
Effect of the COVID-19 Pandemic on Cancer Imaging
Significant decreases in computed tomography (CT) imaging for cancer persisted even after the peak of the COVID-19 pandemic in 2020—delaying diagnosis and treatment and raising the possibility of more advanced cancers and poorer outcomes for patients, according to a study presented at the...
Can Antihistamines Influence Response to Immunotherapy?
New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines was associated with improved responses to immune checkpoint inhibitors. The preclinical study, published by Li et al in Cancer Cell, demonstrated that the histamine receptor H1 (HRH1) acts...
Response to SARS–CoV-2 mRNA Vaccination in Patients With B-Cell Depletion Associated With CAR T-Cell Therapy
In a small single-institution study reported in a research letter in JAMA Oncology, Parvathaneni et al found that SARS–CoV-2 mRNA vaccination produced antibody responses in nearly half—and CD4 T-cell responses in more than half—of patients with B-cell depletion due to treatment with...
Addressing the Global Challenges of Cancer Prevention and Treatment
Nearly 20 million people around the world were diagnosed with cancer in 2020, with 10 million losing their lives to this devastating disease. We highlight here the salient points from our article published in CA: A Cancer Journal for Clinicians,1 which describes the major themes and...
SARC Appoints Jonathan Fletcher, MD, to New Role of Chief Scientific Officer
Sarcoma Alliance for Research Through Collaboration (SARC) recently announced the appointment of Jonathan Fletcher, MD, as Chief Scientific Officer (CSO). This is a new role at the nonprofit cancer research organization, a leader in collaborative discovery, translational research, and clinical...
Shiitake Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, focus on shiitake mushroom ...
Maintenance Daratumumab After Initial Therapy for Transplant-Eligible Multiple Myeloma: More Questions Than Answers From CASSIOPEIA Part 2
Bortezomib, thalidomide, and dexamethasone (VTd) is an acceptable, effective standard-of-care induction treatment in Europe for patients with newly diagnosed myeloma who are eligible for autologous stem cell transplantation. CASSIOPEIA is a two-part, open-label, randomized, phase III trial in...
